Balaxi Pharmaceuticals Q2 Results 2026: PAT ₹1 Cr (+447.6% YoY)
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹81Cr
- +44.8% YoY
- +0.9% QoQ
- Net profit
- ₹1Cr
- +447.6% YoY
- −11.5% QoQ
- Margin
- 6.3%
- +4.2 pp YoY
- +0.5 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Balaxi Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- Reported Revenue from Operations for the quarter ended 30th September 2026: Rs. 8,137.23 Lakhs (Annexure B, Page 8).
As stated in Balaxi Pharmaceuticals Ltd's Q2 FY27 results statement · published 12 Nov 2026. Reported figures, not investment advice.
Based on Balaxi Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Reported Revenue from Operations for the quarter ended 30th September 2026: Rs. 8,137.23 Lakhs (Annexure B, Page 8). EBITDA for the quarter ended 30th September 2026: Rs. 600.3 million, a 45.5% increase year-on-year (YoY).
From Balaxi Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 12 Nov 2026.
How did Balaxi Pharmaceuticals' revenue grow in the September 2026 quarter?
What happened to Balaxi Pharmaceuticals' margins in Q2 FY27?
EBITDA for the quarter ended 30th September 2026: Rs. 600.3 million, a 45.5% increase year-on-year (YoY).
Locked: what Balaxi Pharmaceuticals Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Balaxi Pharmaceuticals planning?
- The Company’s pharmaceutical formulation manufacturing facility at Jadcherla, Hyderabad received WHO-GMP certification from CDSCO, confirming compliance with international standards.
- Commercial production is being progressively scaled up, initially targeting Angola and Dominican Republic markets.
- The facility has manufactured 22 different products so far, with plans to expand the portfolio as regulatory approvals and market demand increase.
2 more points from Balaxi Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Balaxi Pharmaceuticals raising money or cutting debt?
The unaudited standalone cash flow statement (Page 5) shows:
Locked: what Balaxi Pharmaceuticals Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
How big is Balaxi Pharmaceuticals' order book?
See what Balaxi Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Balaxi Pharmaceuticals Ltd — Quarterly revenue & net profit
Balaxi Pharmaceuticals Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 81 |
| Operating profit (EBITDA) | 5 |
| Operating margin | 6.3% |
| Profit before tax | 2 |
| Net profit (PAT) | 1 |
| EPS (₹) | 0.21 |
Source: Balaxi Pharmaceuticals Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹81 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Balaxi Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Innova Captab (Q2 FY27)
Revenue from Operations for Q2 FY27 was ₹496.3 crore, a 30.5% year-on-year (YoY) increase from ₹380.4 crore in Q2 FY26 (Page 11). Key investor presentation take
- Viyash Scientific (Q2 FY27)
Q2 FY27 revenue from operations: ₹9,879 million, up 16.2% YoY (Page 8) . Key investor presentation takeaways from Viyash Scientific Ltd's Q2 FY27 investor prese
- Natco Pharma (Q2 FY27)
EBITDA for Q2 FY27: INR 3,100 Mn, down from INR 6,792 Mn in Q2 FY26 (54.4% decline) . Key investor presentation takeaways from Natco Pharma Ltd's Q2 FY27 invest
- Vineet Laborator (Q2 FY27)
Year-on-year change: Decrease of approximately INR 323.65 lakh or about 18.58% decline . Key results statement takeaways from Vineet Laboratories Ltd's Q2 FY27
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Balaxi Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Balaxi Pharmaceuticals Ltd Q2 FY27 results?
Reported Revenue from Operations for the quarter ended 30th September 2026: Rs. 8,137.23 Lakhs (Annexure B, Page 8). EBITDA for the quarter ended 30th September 2026: Rs. 600.3 million, a 45.5% increase year-on-year (YoY).
What is Balaxi Pharmaceuticals Ltd share price analysis?
Balaxi Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 54.2 with a market cap of ₹132 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaxi Pharmaceuticals Ltd planning capital expenditure?
The Company’s pharmaceutical formulation manufacturing facility at Jadcherla, Hyderabad received WHO-GMP certification from CDSCO, confirming compliance with international standards.
Keep Balaxi Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.